The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites

American Journal of Gastroenterology

Volumn 100, Issue 4, 2005, Pages 879-885

  Kalambokis, Georgios ^b   Economou, Michalis ^b   Fotopoulos, Andreas ^b   Al Bokharhii, Jihad ^b   Pappas, Christos ^b   Katsaraki, Afroditi ^b   Tsianos, Epameinondas V ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; FUROSEMIDE; GLUCAGON; MIDODRINE; OCTREOTIDE; RENIN; SPIRONOLACTONE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; GLUCAGON BLOOD LEVEL; HEART INDEX; HEART RATE; HEMODYNAMICS; HUMAN; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY VASCULAR RESISTANCE; LIVER CIRRHOSIS; LONG TERM CARE; MALE; MEAN ARTERIAL PRESSURE; MONOTHERAPY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIDE EFFECT; SYSTEMIC VASCULAR RESISTANCE; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; BLOOD FLOW; BLOOD FLOW VELOCITY; COMPARATIVE STUDY; DRUG COMBINATION; HEPATORENAL SYNDROME; KIDNEY; KIDNEY FUNCTION TEST; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VASCULAR RESISTANCE; VASCULARIZATION;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-AGONISTS; ADULT; AGED; ALDOSTERONE; BLOOD FLOW VELOCITY; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GLUCAGON; HEMODYNAMIC PROCESSES; HEPATORENAL SYNDROME; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MIDODRINE; OCTREOTIDE; REGIONAL BLOOD FLOW; RENIN; VASCULAR RESISTANCE;

EID: 17544380014     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.40899.x     Document Type: Article

References (45)

1. Schrier R, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
2. Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989;97:1304-12.
3. Martin PY, Gines P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998;339:533-41.
4. Piccueta MP, Casamitjana R, Bosch J, et al. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: Role of hyperglucagonism. Am J Physiol 1990;258:G191-5.
5. Arroyo V, Jimenez W. Complications of cirrhosis.II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000;32(Suppl 1):157-70.
6. Gadano A, Moreau R, Vachiery F, et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J Hepatol 1997;26:1229-34.
7. Angeli P, Volpin R, Piovan D, et al. Acute effects of the oral administration of midodrine, an α-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998;28:937-43.
8. Uriz J, Gines P, Gardenas A, et al. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol 2000;33:33-48.
9. Angeli P, Volpin R, Gerounda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999;29:1690-7.
10. Duvoux C, Zanditenas D, Hezode C, et al. Effects of no-radrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study. Hepatology 2002;36:374-80.
11. Ryan J, Sudhir K, Jennings G, et al. Impaired reactivity of peripheral vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology 1993;105:1167-72.
12. McTavish D, Goa K. Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs 1989;38:757-77.
13. Tsuchida K, Yamazaki R, Kaneko K, et al. Effects of midodrine on blood flow in dog vascular beds. Arzneimittelforschung 1986;36:1745-8.
14. Bauer W, Briner U, Doepfher W, et al. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982;31:1133-40.
15. Sieber CC, Lee FY, Groszmann RJ. Long-term octreotide treatment prevents vascular hyporeactivity in portal hypertensive rats. Hepatology 1996;23:1218-23.
16. Malesci A, Tacconi M, Valentini A, et al. Octreotide long-term treatment in patients with portal hypertension: Persistent inhibition of postprandial glucagon response without major changes in renal function. J Hepatol 1997;26:816-25.
17. Gines A, Salmeron JM, Gines P, et al. Effects of somatostatin on renal function in cirrhosis. Gastroenterology 1992;103:1868-74.
18. McCormick PA, Chin J, Greenslade L, et al. Cardiovascular effect of octreotide in patients with hepatic cirrhosis. Hepatology 1995;21:1255-60.
19. Moller S, Brinch Kim, Henriksen JH, et al. Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis. J Hepatol 1997;26:1026-33.
20. Lin HC, Tsai YT, Lee FY, et al. Hemodynamic evaluation of octreotide in patients with hepatitis-B-related cirrhosis. Gastroenterology 1992;103:229-34.
21. Lin HC, Tsai YT, Huang CC, et al. Effects of octreotide on post-prandial systemic and hepatic hemodynamics in patients with postnecrotic cirrhosis. J Hepatol 1994;21:424-9.
22. Sabat M, Guarner C, Soriano G, et al. Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites. Dig Dis Sci 1998;43:2184-9.
23. Rodriguez-Perez F, Albillos A, Groszmann RJ. Octreotide improves renal function, total exchangeable sodium and peripheral hemodynamics in cirrhotic patients with ascites (abstract). Gastroenterology 1993;104:980A.
24. + retention in portal hypertensive rats. Gastroenterology 1993;104:575-9.
25. Mountokalakis T, Kallivretakis N, Mayopoulou-Symvoulidou D, et al. Enhancement of renal function by a long-acting somatostatin analogue in patients with decompensated cirrhosis. Nephrol Dial Transplant 1988;3:604-7.
26. Selzer R, Dudley F. Effects of octreotide on renal function in cirrhosis: reversal with glucagon (abstract). Hepatology 1993;18:102A.
27. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996;23:164-76.
28. Blaufox MD. Measurement of renal function with radioactive materials. In: Blaufox MD, ed. Evaluation of renal function and disease with radionuclides. The upper urinary tract. Basel: Karger, 1989:12-27.
29. Yang YY, Lin HC, Huang YT, et al. Adaptive vasodilatory response of octreotide in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol 2001;281:G117-23.
30. Categaro L, Menon F, Angeli P, et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med 1994;154:201-7.
31. Rehling M, Moller ML, Thamdrup B, et al. Simultaneous measurement of renal clearance and plasma clearance of 99mTc-labelled diethylenetriaminepenta- acetate, 51Cr-labelled ethylenediaminetetra-acetate and inulin in man. Clin Sci 1984;66:613-9.
32. Levey AS, Madaio MP, Perrone RD. Laboratory assessment of renal disease: Clearance, urinalysis, and renal biopsy. In: Brenner BM, Rector FC Jr, eds. The kidney, 4th Ed. Philadelphia: Saunders;1991:919-68.
33. Wang SS, Lee FY, Wu SL, et al. Effects of long-term administration of octreotide on sodium retention and atrial natriuretic peptide in carbon tetrachloride-induced cirrhotic rats. J Hepatol 1997;26:1128-34.
34. Rosenthal J, Escobar-Jimenez F, Raptis S, et al. Inhibition of furosemide induced hyperreninemia by growth hormone release inhibiting hormone in man. Lancet 1976;1:772-4.
35. Rosenthal J, Escobar-Jimenez F, Raptis S. Prevention of somatostatin rise in blood pressure and plasma renin activity mediated by beta-receptor stimulation. Clin Endocrinol 1977;6:455-62.
36. Arlart I, Rosenthal J, Pal S, et al. Einfluss von Somatostatin auf Renin, Aldosteron und Blutdruck bei unilateraler renovaskularer Hypertonie. Verhandl Deutsh Gesell Inn Med 1978;84:824-7.
37. Sieber C, Gnadinger M, del Pozo E, et al. Effect of a new Somatostatin analogue SMS 201-995 (sandostatin) on the renin-aldosterone axis. Clin Endocrinol 1988;28:25-32.
38. Izumi Y, Honda M, Hartano M. Effect of somatostatin on plasma renin activity. Endocrinol Jpn 1979;26:389-94.
39. Kurokawa K, Aponte G, Fujibayashi S, et al. Somatostatin-like immunoreactivity in the glomerulus of rat kidney. Kidney Int 1983;24:754-7.
40. Aguilera G, Parker DS, Gatt KJ. Characterization of somatostatin receptors in rat adrenal glomerulosa zone. Endocrinology 1982;111:1376-82.
41. Jones CR, Millar JA, Lawrie C, et al. Specific inhibition of aldosterone responses to endogenous and exogenous angiotensin II by somatostatin. Clin Endocrinol 1984;21:279-84.
42. Aguilera G, Parker DS, Gatt KJ. Somatostatin modulates effects of Angiotensin II in adrenal glomerulosa zone. Nature 1982;292:262-3.
43. Hall JE, Guyton AC, Jackson TE, et al. Control of glomerular filtration rate by renin-angiotensin system. Am J Physiol 1977;233:F366-72.
44. Gentilini P, Romanelli RG, La Villa G, et al. Effects of low-dose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 1993;104:588-94.
45. Gines P, Ortega R, Uritz J, et al. Effects of terlipressin administration with and without albumin in hepatorenal syndrome (HRS). A phase-II study (abstract). Hepatology 2001;34:186A.